John P. Hamill

John P. Hamill is a declared insider at 2 companies (finance chief); the most frequent names are Aprea Therapeutics, Inc. and Windtree Therapeutics Inc. Over a trading history stretching from 4 March 2022 to 12 March 2026, the count stands at 12 filings.

On the market, this insider has only ever bought: 6 purchases, €18k in total. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The rest of the record consists of 6 share grants. So far in 2026, the count stands at 1 purchase and no sales.

In size, the median ticket on the buying side is €2,663. Clusters matter here: 6 out of 6 purchases overlapped with buying by a colleague within 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

On 16 March 2026 came the latest disclosure, a share grant in Aprea Therapeutics, Inc. The latest purchase dates back some time: it was published 258 days ago, on 2 February 2026. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.